623 related articles for article (PubMed ID: 26525804)
1. Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: Two-year clinical outcome of the randomized ROTAXUS trial.
de Waha S; Allali A; Büttner HJ; Toelg R; Geist V; Neumann FJ; Khattab AA; Richardt G; Abdel-Wahab M
Catheter Cardiovasc Interv; 2016 Mar; 87(4):691-700. PubMed ID: 26525804
[TBL] [Abstract][Full Text] [Related]
2. High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial.
Abdel-Wahab M; Richardt G; Joachim Büttner H; Toelg R; Geist V; Meinertz T; Schofer J; King L; Neumann FJ; Khattab AA
JACC Cardiovasc Interv; 2013 Jan; 6(1):10-9. PubMed ID: 23266232
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
[TBL] [Abstract][Full Text] [Related]
4. High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions.
Abdel-Wahab M; Toelg R; Byrne RA; Geist V; El-Mawardy M; Allali A; Rheude T; Robinson DR; Abdelghani M; Sulimov DS; Kastrati A; Richardt G
Circ Cardiovasc Interv; 2018 Oct; 11(10):e007415. PubMed ID: 30354632
[TBL] [Abstract][Full Text] [Related]
5. Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial.
Généreux P; Bettinger N; Redfors B; Lee AC; Kim CY; Lee MS; Shlofmitz RA; Moses JW; Stone GW; Chambers JW
Catheter Cardiovasc Interv; 2016 Sep; 88(3):369-77. PubMed ID: 27084293
[TBL] [Abstract][Full Text] [Related]
6. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcomes of permanent-polymer everolimus-eluting stent implantation following rotational atherectomy for severely calcified de novo coronary lesions: Results of a 22-center study (Tokyo-MD PCI Study).
Otaki Y; Ashikaga T; Sasaoka T; Kurihara K; Yoshikawa S; Isobe M;
Cardiovasc Revasc Med; 2019 Feb; 20(2):120-125. PubMed ID: 29861332
[TBL] [Abstract][Full Text] [Related]
8. Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial.
Lee M; Généreux P; Shlofmitz R; Phillipson D; Anose BM; Martinsen BJ; Himmelstein SI; Chambers JW
Cardiovasc Revasc Med; 2017 Jun; 18(4):261-264. PubMed ID: 28162989
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
10. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
11. Orbital Atherectomy for the Treatment of Long (≥25-40 mm) Severely Calcified Coronary Lesions: ORBIT II Sub-Analysis.
Kumar G; Shin EY; Sachdeva R; Shlofmitz E; Behrens AN; Martinsen BJ; Chambers JW
Cardiovasc Revasc Med; 2020 Feb; 21(2):164-170. PubMed ID: 32014391
[TBL] [Abstract][Full Text] [Related]
12. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: a randomized PIPA trial.
Kim HS; Park SJ; Park DW; Park SW; Cheong SS; Lee SG; Cho BR; Lee SW; Lee NH; Lee K;
Catheter Cardiovasc Interv; 2012 Nov; 80(5):799-806. PubMed ID: 22120995
[TBL] [Abstract][Full Text] [Related]
14. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
15. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
[TBL] [Abstract][Full Text] [Related]
16. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
17. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
18. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
[TBL] [Abstract][Full Text] [Related]
20. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
